Export-valued At 107 Million US Dollars, Bio Farma Exports Have Won 153 Countries
JAKARTA - PT Bio Farma (Persero) emphasized its business growth through export activities to more than 153 countries. One of them is through the polio vaccine.
Bio Farma President Director Honesti Basyir said that Bio Farma products have international standards and have been exported to more than 153 countries. In fact, he said, the need for 70 percent of polio vaccines in the world is met by Bio Farma.
"Bio Farma has produced quality vaccines according to World Health Organization (WHO) standards," he said in a written statement, Tuesday, December 20.
Honesti added that Bio Farma has increased Indonesia's role in developing countries that are members of the Development Countries Vaccine Management Network (DCVMN) and the Organization of Islamic Cooperation (OIC) to produce vaccines that are of high quality at affordable prices.
"The realization of exports of Bio Farma products in 2021 has increased from the previous 69 million US dollars in 2020 to 107 million US dollars," said Honesti.
On a different occasion, Bio Farma Research & Development Director Yuliana Indriati said that Bio Farma's exports were mainly through agencies under the United Nations (UN) such as UNICEF, as well as through bilateral cooperation with Asian and African countries.
Yuliana added that Bio Farma's export products include finished products such as nOPV2 vaccines, Hepatitis B vaccines, TT vaccines, TD vaccines, as well as other leading vaccine products. As well as bulk products such as Polio Bulk, Ricees Bulk, Tetanus Bulk and others. Bio Farma also has export product portfolios in the form of Diagnostic Kits such as Bio VTM, BioCov-19 and mBioCov-19 for PCR Kites, as well as BioColomelt for Cancer Kit.
Bio Farma is also aggressively collaborating with Global Partners, such as with the Profactor Pharma (United Kingdom) whose signing of the cooperation will be held in September 2022. Through this collaboration, Bio Farma will act as an exclusive manufacturing for global supply cooperation for the Recombinant Factor VII product.
Most recently, Bio Farma has signed an agreement with Merck & Co Inc (MSD), a global player from the United States for technology transfer cooperation to produce the Human Papillomavirus (HPV) Vaccine needed to accelerate the response to cervical cancer in Indonesia.